Compare SGRP & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRP | LSTA |
|---|---|---|
| Founded | 1967 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 16.4M |
| IPO Year | 1996 | N/A |
| Metric | SGRP | LSTA |
|---|---|---|
| Price | $0.82 | $2.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 67.6K | 40.9K |
| Earning Date | 11-14-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $147,130,000.00 | $1,070,000.00 |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.79 | N/A |
| 52 Week Low | $0.76 | $1.81 |
| 52 Week High | $2.10 | $4.11 |
| Indicator | SGRP | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 56.25 |
| Support Level | $0.77 | $1.84 |
| Resistance Level | $0.92 | $2.27 |
| Average True Range (ATR) | 0.04 | 0.14 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 41.92 | 72.41 |
SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. It also provides a range of services to retailers, consumer goods manufacturers and distributors around the globe. The company divides its operations into three reportable regional segments: Americas, which is comprised of United States, Canada, Brazil and Mexico; Asia-Pacific (APAC), which is comprised of Japan, China, and India; and Europe, Middle East and Africa (EMEA), which is comprised of South Africa. It generates maximum revenue from the Americas.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.